COVID-19 clinical vaccine study

ARC enrolling for COVID-19 variants vaccine trial

ARC Clinical Research is participating in a COVID-19 vaccine study testing an “updated” Pfizer‐BioNTech vaccine targeting specific variants.

Why are COVID-19 clinical trials needed?

“As new variants emerge with unknown risk, such as the latest Omicron, we must continue to research new approaches to ensure that our vaccines can adequately protect against COVID-19,” said Amy B. Siegel, MD, ARC Internal Medicine physician and ARC Clinical Research Principal Investigator. “If evidence emerges that the existing vaccines are less effective against the variants, trials like this one will make us better prepared.”

Volunteers may be eligible to participate if they:

  • Are a man or non-pregnant woman 18 years to 85 years old
  • Have previously received the BNT162b2 vaccine* (also known as the Pfizer-BioNTech vaccine; 30 μg, two dose regimen) at least 6 months ago
  • Have not previously received vaccination for COVID 19
  • Have no history of COVID-19 and/or clinical or microbiological evidence of prior infection at screening
  • Have no known history of HBV or HIV
  • Have no known history of cardiovascular diseases
  • Have had no previous allergic reactions to vaccines

There are other requirements for taking part in this clinical study. The study team will discuss these other criteria with you.

ARC Clinical Research is the only site in Central Texas recruiting for the BioNTech clinical trial.

Clinical trial spots are limited!

If you are interested in participating, contact ARC Wilson Parke Clinical Research at 512-225-5931 or click here to learn more about the study and how to enroll in these clinical trials.

Tags: COVID-19

More on this Topic

What have we learned in two years of COVID-19?

Anas Daghestani, MD, ARC CEO, and Amy B. Siegel, MD, ARC Internal Medicine and ARC Clinical Researcher, share their thoughts and lessons from the last two years of the pandemic in this recent article.

FDA approves first COVID treatment pill

This week, the Food and Drug Administration authorized the first antiviral pill, Paxlovid, to treat COVID-19 at home. Learn more.

Keeping you up to date on the COVID-19 kids vax

Elizabeth C. Knapp, MD, Pediatrics at ARC Far West, sat down to talk to Spectrum News about the latest news on the COVID-19 vaccine for kids ages 5-11 years old. Hear what she has to say about the efficacy and safety of this shot for children.

Protecting our youngest children from COVID-19

The only way we can protect our children is to make sure that everybody is wearing their mask, socially distancing, and vaccinated when possible. See what else Dr. Elizabeth Knapp has to say about protecting our vulnerable community members.

Back-to-school and COVID: bringing the risk home

A look at the COVID risk factors in households with school age children. Dr. Sunaina Suhag and Dr. David Gray talk about how back-to-school affects the entire household?